A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.

[1]  Kuen-Feng Chen,et al.  Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. , 2011, Journal of hepatology.

[2]  Kuen-Feng Chen,et al.  Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. , 2011, European journal of medicinal chemistry.

[3]  J. Llovet,et al.  Targeted therapies for hepatocellular carcinoma. , 2011, Gastroenterology.

[4]  G. Sethi,et al.  γ‐Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro‐apoptotic and chemosensitizing agent , 2011, British journal of pharmacology.

[5]  P. Gunning,et al.  Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report , 2011, Anti-cancer drugs.

[6]  Taher Abbasi,et al.  Suppression of Signal Transducer and Activator of Transcription 3 Activation by Butein Inhibits Growth of Human Hepatocellular Carcinoma In Vivo , 2010, Clinical Cancer Research.

[7]  Kuen-Feng Chen,et al.  Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3 , 2010, Clinical Cancer Research.

[8]  B. Aggarwal,et al.  Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP‐1 in human multiple myeloma cells , 2010, International journal of cancer.

[9]  G. Sethi,et al.  Identification of β-Escin as a Novel Inhibitor of Signal Transducer and Activator of Transcription 3/Janus-Activated Kinase 2 Signaling Pathway that Suppresses Proliferation and Induces Apoptosis in Human Hepatocellular Carcinoma Cells , 2010, Journal of Pharmacology and Experimental Therapeutics.

[10]  Lillian L. Siu,et al.  Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma , 2010, Clinical Cancer Research.

[11]  C. Rudin,et al.  A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies , 2010, Cancer Chemotherapy and Pharmacology.

[12]  B. Aggarwal,et al.  5-Hydroxy-2-Methyl-1,4-Naphthoquinone, a Vitamin K3 Analogue, Suppresses STAT3 Activation Pathway through Induction of Protein Tyrosine Phosphatase, SHP-1: Potential Role in Chemosensitization , 2010, Molecular Cancer Research.

[13]  R. Labianca,et al.  The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  H. Hsieh,et al.  Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway* , 2009, Journal of Biological Chemistry.

[15]  J. Prieto,et al.  Inflammation and Liver Cancer , 2009, Annals of the New York Academy of Sciences.

[16]  B. Cheson,et al.  Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. , 2009, Blood.

[17]  B. Aggarwal,et al.  Boswellic Acid Blocks Signal Transducers and Activators of Transcription 3 Signaling, Proliferation, and Survival of Multiple Myeloma via the Protein Tyrosine Phosphatase SHP-1 , 2009, Molecular Cancer Research.

[18]  S. Arii,et al.  Molecularly targeted therapy for hepatocellular carcinoma , 2009, Cancer science.

[19]  B. Cheson,et al.  A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies , 2008, Clinical Cancer Research.

[20]  J. Naval,et al.  Bcl-2 family members as molecular targets in cancer therapy. , 2008, Biochemical pharmacology.

[21]  T. Bagnyukova,et al.  Epigenetic down-regulation of the suppressor of cytokine signaling 1 (Socs1) gene is associated with the STAT3 activation and development of hepatocellular carcinoma induced by methyl-deficiency in rats , 2008, Cell cycle.

[22]  J. Bruix,et al.  Molecular targeted therapies in hepatocellular carcinoma , 2008, Hepatology.

[23]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[24]  D. Germain,et al.  Targeting the Cytoplasmic and Nuclear Functions of Signal Transducers and Activators of Transcription 3 for Cancer Therapy , 2007, Clinical Cancer Research.

[25]  K. Eguchi,et al.  Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. , 2007, Journal of hepatology.

[26]  G. Gores,et al.  Piercing the armor of hepatobiliary cancer: Bcl‐2 homology domain 3 (BH3) mimetics and cell death , 2007, Hepatology.

[27]  Didier Merlin,et al.  Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. , 2007, Cancer research.

[28]  M. Wasik,et al.  Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma. , 2007, Human pathology.

[29]  Hong Zhang,et al.  Inhibition of Growth and Metastasis of Human Hepatocellular Carcinoma by Antisense Oligonucleotide Targeting Signal Transducer and Activator of Transcription 3 , 2006, Clinical Cancer Research.

[30]  R. Lai,et al.  Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. , 2006, Blood.

[31]  Y. Maehara,et al.  Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. , 2006, Gastroenterology.

[32]  T. Russo,et al.  Redox Control of Signal Transduction, Gene Expression and Cellular Senescence , 2004, Neurochemical Research.

[33]  C. Wu,et al.  SHP‐1 suppresses cancer cell growth by promoting degradation of JAK kinases , 2003, Journal of cellular biochemistry.

[34]  Lijun Liu,et al.  The function of the protein tyrosine phosphatase SHP-1 in cancer. , 2003, Gene.

[35]  C. Röpke,et al.  Suppressors of cytokine signalling: SOCS , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[36]  S. Matsuda,et al.  Bcl-xL overexpression in human hepatocellular carcinoma. , 2002, International journal of oncology.

[37]  S. Friedman,et al.  Expression and role of Bcl‐xL in human hepatocellular carcinomas , 2001, Hepatology.

[38]  Ziwei Huang,et al.  Bcl-2 family proteins as targets for anticancer drug design , 2000, Oncogene.

[39]  N. Tonks,et al.  Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. , 1991, Science.

[40]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[41]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[42]  M. Peck-Radosavljevic,et al.  Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. , 2006, Journal of hepatology.

[43]  P. Galle,et al.  Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. , 2006, International journal of oncology.